Tempest Therapeutics, Inc.
Tempest Therapeutics, Inc. (TPST): 9 pipeline candidates · 1 upcoming catalyst · ~1 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
0.9 months
D/E 12.08 · 0% dilution
Lead: Phase 3
9 candidates
1 upcoming, next in ~1474d
1 buy · 0 sells (180d)
A transparent, data-derived signal for Tempest Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$19.1M
Cash
$2.2M
Quarterly Burn
$7.6M
Runway
0.9 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (9 candidates)
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
20
Total value held
$1.2M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 467,776 | $767K |
| geode capital management, llc | 86,990 | $143K |
| vanguard fiduciary trust co | 68,908 | $113K |
| blackrock, inc. | 39,068 | $64K |
| fmr llc | 33,225 | $54K |
| sabby management, llc | 17,856 | $29K |
| northern trust corp | 14,053 | $23K |
| dimensional fund advisors lp | 11,444 | $19K |
| tower research capital llc (trc) | 2,790 | $5K |
| morgan stanley | 2,058 | $3K |
Showing top 10 of 20 institutional holders of Tempest Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Tempest Therapeutics, Inc.'s pipeline?
Tempest Therapeutics, Inc. (TPST) has 9 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Tempest Therapeutics, Inc.'s lead drug candidate?
Tempest Therapeutics, Inc.'s most advanced tracked candidate is amezalpat (Phase 3) for first-line unresectable or metastatic hepatocellular carcinoma (HCC).
What is Tempest Therapeutics, Inc.'s next catalyst?
Tempest Therapeutics, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of TPST-1120 in Combination With Atezol" — expected July 1, 2030.
What is Tempest Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Tempest Therapeutics, Inc. has approximately 0.9 months of cash runway.
What is Tempest Therapeutics, Inc.'s market capitalization?
Tempest Therapeutics, Inc.'s market capitalization is approximately $19.1M.
Get the full picture on Tempest Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.